uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
February 27, 2023 07:05 ET
|
uniQure Inc.
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington’s disease –...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 23, 2023 08:05 ET
|
uniQure Inc.
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
February 21, 2023 07:05 ET
|
uniQure Inc.
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
January 31, 2023 07:05 ET
|
uniQure Inc.
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2022 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
December 16, 2022 07:15 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
November 29, 2022 11:00 ET
|
uniQure Inc.
~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands,...
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
November 22, 2022 16:40 ET
|
uniQure Inc.
~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX...
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
November 17, 2022 07:05 ET
|
uniQure Inc.
~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 02, 2022 07:05 ET
|
uniQure Inc.
~ Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation ~~ U.S. and European pre-approval inspections of...